Overview

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
0
Participant gender:
Male
Summary
Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were separated by a washout period of 11 days.
Phase:
Phase 1
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Torrent Pharmaceuticals Limited
Treatments:
Nebivolol
Criteria
Inclusion Criteria:

- Sex: male

- Age: 18-45 years (inclusive both)

- Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.

- Healthy and willing to participate in the study.

- Volunteer willing to adhere to the protocol requirements and to provide written
informed consent.

- Non-smokers or smoker who smokes less than 10 cigarettes per day.

Exclusion Criteria:

- Inability to communicate or co-operate.

- Volunteers suffering from any chronic illness such as arthritis, asthma etc.

- History of pre-existing bleeding disorder.

- Clinically relevant abnormalities in the results of the laboratory screening
evaluation.

- Clinically significant abnormal ECG or Chest X-ray.

- HIV, HCV, HBsAg positive volunteers.

- History of significant blood loss due to any reason, including blood donation in the
past 3 months.

- Participation in any study within past 3 months before entry to the study,

- History of alcohol or drug abuse.

- History of consumption of prescribed medication since last 14days or OTC medication/
herbal remedies since last 7 days before beginning of the study.

- Positive to breath alcohol test.

- Volunteer found to be positive for Opiate, tetra hydrocannabinol, amphetamine,
barbiturates, benzodiazepines, Cocaine positive volunteers based on urine test.

- Systolic blood pressure less than 100 mmHg or more than 140 mmHg and diastolic blood
pressure less than 60 mm Hg or more than 90 mm Hg.

- Pulse rate less than 50/minute or more than 100/minute.

- Oral temperature less than 95°F or more than 98.6°F.

- Respiratory rate less than 12/minute or more than 20/minute.

- History of allergy to the test drug or any drug chemically similar to the drug under
investigation.

- Recent History of kidney or liver dysfunction.

- Volunteers suffering from any psychiatric (acute or chronic) disorder.

- Existence of any surgical or medical condition, which, in the judgment of the Chief
Investigator and/or clinical investigator/physician, might interfere with the
absorption; distribution,· metabolism or excretion of the drug or likely to compromise
the safety of Volunteers.